A phase 1, first-in-human, dose escalation and expansion study to evaluate the safety and tolerability of XmAb541 (claudin-6 x CD3) T-cell engaging bispecific antibody in subjects with germ cell tumors and other advanced solid tumors

• Published in: Journal of clinical oncology Vol. 43; no. 5_suppl; p. TPS652
• Main Authors: Gutierrez, Martin, Winer, Ira Seth, Reilley, Matthew, Duska, Linda R., Subbiah, Vivek, Richardson, Debra L., Bohac, Chet, CHIARELLA, MICHAEL, Naranjo, Carlos, Kanodia, Jitendra, Woo, Jacky, Nevadunsky, Nicole
• Format: Journal Article
• Language: English
• Published: American Society of Clinical Oncology 10.02.2025

TPS652Background: Claudin-6 (CLDN6) is overexpressed in solid tumors including germ cell tumors (GCTs) with minimal expression in healthy tissue. This differential expression profile makes CLDN6 a suitable tumor-associated antigen for a T-cell engaging bispecific antibody (bsAb). XmAb541 is a first-...